Mineralys Therapeutics acquires lorundrostat intellectual property from Tanabe Pharma
MLYS•Mineralys Therapeutics acquired lorundrostat patents and know-how from Tanabe Pharma on October 27, 2026, ending their license agreement. Remaining obligations include up to $255 million in commercial milestones and up to $10 million for a potential second indication.
1. Acquisition terms
Mineralys Therapeutics acquired lorundrostat patents and know-how from Tanabe Pharma on October 27, 2026, terminating their license agreement. Remaining obligations include commercial milestones of up to $255 million and up to $10 million for a potential second indication. Qualifying changes of control or exclusive licensing deals that include U.S. rights would accelerate $100 million of milestone payments. Tanabe retains first-negotiation rights for lorundrostat licenses in Japan while milestones remain unachieved and corresponding payments remain unpaid.
